Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,364 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Syringe Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity

NCT01728792
View directory record Official record
Conditions
Dengue Fever
Interventions
TDV
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 28, 2026, 10:42 AM EDT
Terminated Phase 3 Interventional Results available

Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)

NCT03668600
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
74
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 28, 2026, 10:42 AM EDT
Available No phase listed Expanded access

A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema

NCT01487044
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Macugen (Pegaptanib Sodium)
Drug
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Oct 28, 2026, 10:42 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

NCT07416604
View directory record Official record
Conditions
Hemophilia A
Interventions
NXT007, Emicizumab
Combination Product · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
10
States / cities
Orange, California • Aurora, Colorado • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 10:42 AM EDT
Completed Not applicable Interventional Results available

Reciprocating Medical Devices - a Study of a New Safety Device

NCT00651625
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Trauma, Thyroid Nodule, Cancer
Interventions
Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001, conventional syringe - BD Ref 309604
Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 28, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional Results available

ACZ885 for the Treatment of Abdominal Aortic Aneurysm

NCT02007252
View directory record Official record
Conditions
Abdominal Aortic Aneurysm (AAA)
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 28, 2026, 10:42 AM EDT
Recruiting Not applicable Interventional

Comprehensive HIV and Harm Prevention Via Telehealth

NCT05897099
View directory record Official record
Conditions
HIV Infections
Interventions
Comprehensive Tele-harm Reduction, Off-site Linkage to HIV Prevention
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 28, 2026, 10:42 AM EDT
Completed Not applicable Interventional

Rx Milk Study of Donor Milk Supplementation to Improve Breastfeeding Outcomes

NCT02221167
View directory record Official record
Conditions
Breastfeeding Duration, Exclusive Breastfeeding, Donor Milk Supplementation
Interventions
Donor Milk
Other
Lead sponsor
Laura Kair
Other
Eligibility
24 Hours to 48 Hours
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 16, 2018 · Synced Oct 28, 2026, 10:42 AM EDT
Completed Phase 2 Interventional

Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)

NCT04505436
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HM15211, Placebo of HM15211
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
48
States / cities
Huntsville, Alabama • Chandler, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 28, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

NCT04133909
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
88
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 72 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 28, 2026, 10:42 AM EDT
Completed Phase 4 Interventional Results available

BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

NCT00326963
View directory record Official record
Conditions
HIV Infections
Interventions
Background ARVs, PI, enfuvirtide [Fuzeon]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
32
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 28, 2026, 10:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

NCT00254293
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept or Placebo (both as IV & SC solution), Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
5
States / cities
Orlando, Florida • Atlanta, Georgia • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 28, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants

NCT03461406
View directory record Official record
Conditions
Excessive Bleeding During Surgery
Interventions
Fibrin Sealant Grifols, EVICEL
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
Up to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
12
States / cities
Chicago, Illinois • Michigan Center, Michigan • Albany, New York + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 28, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-2060 in Healthy Participants (MK-2060-016)

NCT06582602
View directory record Official record
Conditions
Venous Thrombosis
Interventions
MK-2060, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 28, 2026, 10:42 AM EDT
Active, not recruiting Not applicable Interventional

The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City

NCT06316739
View directory record Official record
Conditions
HIV Infections, HCV, Overdose
Interventions
Ganchero intervention
Behavioral
Lead sponsor
North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI)
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 28, 2026, 10:42 AM EDT
Not listed Not applicable Interventional

Efficacy of a Single Injection of CTM for Post-Operative CMC Arthritis

NCT06171529
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis Thumb Base Joint, Carpometacarpal Osteoarthritis, Thumb
Interventions
CTM, Placebo
Device · Other
Lead sponsor
Indiana Hand to Shoulder Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 28, 2026, 10:42 AM EDT
Completed Early Phase 1 Interventional

Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery System

NCT04410237
View directory record Official record
Conditions
Psoriasis
Interventions
Med-Jet, Traditional Syringe
Device · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 28, 2026, 10:42 AM EDT
Recruiting Not applicable Interventional

A Study to Evaluate the Cariostatic Efficacy of Nano Silver Fluoride (NSF) vs. Silver Diamine Fluoride (SDF) in Children

NCT07861321
View directory record Official record
Conditions
Dental Caries
Interventions
Nano Silver Fluoride / NSF
Device
Lead sponsor
A.T. Still University of Health Sciences
Other
Eligibility
6 Years to 10 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Extension in AS: Sustainability of Benefits, Safety and Tolerability

NCT01863732
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Secukinumab, Placebo (Pbo)
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Portland, Oregon • Duncansville, Pennsylvania • Jackson, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 28, 2026, 10:42 AM EDT
Active, not recruiting Not applicable Interventional

Open Pilot Trial of Adapted Cognitive Processing Therapy for Comorbid PTSD and Opioid Use Disorder

NCT06872164
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD), Opioid Use Disorder
Interventions
Cognitive Processing Therapy
Behavioral
Lead sponsor
The City College of New York
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 28, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

NCT04978454
View directory record Official record
Conditions
Influenza
Interventions
Influenza RG-A/Texas/71/2017 (H3N2) Challenge, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 28, 2026, 10:42 AM EDT
Terminated Phase 3 Interventional Results available

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

NCT01764997
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Etanercept, Methotrexate, Placebo (for sarilumab), Placebo (for etanercept), Adalimumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Birmingham, Alabama • Glendale, California • Thousand Oaks, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 28, 2026, 10:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT00397579
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions
DT388IL3
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 28, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder

NCT02951988
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo-matching Rapastinel
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
137
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 112 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 28, 2026, 10:42 AM EDT